- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Fred Alger Management LLC Buys $26.35M Stake in Veracyte
Institutional investor takes large position in biotech firm
Mar. 16, 2026 at 10:18am
Got story updates? Submit your updates here. ›
Fred Alger Management LLC has acquired a new position in shares of Veracyte, Inc. (NASDAQ:VCYT), purchasing 767,479 shares valued at approximately $26.35 million. This represents a 0.97% stake in the biotechnology company.
Why it matters
The purchase by the institutional investor suggests confidence in Veracyte's growth potential and future prospects. As a major shareholder, Fred Alger Management LLC will likely have increased influence over the company's strategic direction.
The details
According to a recent SEC filing, Fred Alger Management LLC bought the new position in Veracyte during the third quarter. The investment firm now owns 0.97% of the biotechnology company's outstanding shares.
- The purchase was made in the third quarter of the fiscal year.
The players
Fred Alger Management LLC
An institutional investment management firm that has taken a significant stake in Veracyte, Inc.
Veracyte, Inc.
A biotechnology company that develops and commercializes genomic tests to aid in the diagnosis of various diseases.
The takeaway
The investment by Fred Alger Management LLC in Veracyte signals confidence in the biotech firm's growth prospects and future potential. As a major shareholder, the institutional investor will likely play a more active role in shaping the company's strategic direction going forward.
